CN105661509A - Krill oil softgel for protecting bone health as well as preparation method and application thereof - Google Patents
Krill oil softgel for protecting bone health as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105661509A CN105661509A CN201610028631.3A CN201610028631A CN105661509A CN 105661509 A CN105661509 A CN 105661509A CN 201610028631 A CN201610028631 A CN 201610028631A CN 105661509 A CN105661509 A CN 105661509A
- Authority
- CN
- China
- Prior art keywords
- krill oil
- calcium
- preparation
- soft capsule
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940106134 krill oil Drugs 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000037180 bone health Effects 0.000 title claims abstract description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000011575 calcium Substances 0.000 claims abstract description 38
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 38
- 239000002775 capsule Substances 0.000 claims abstract description 16
- 150000002301 glucosamine derivatives Chemical class 0.000 claims abstract description 15
- 238000000265 homogenisation Methods 0.000 claims abstract description 9
- 238000000465 moulding Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 239000007901 soft capsule Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 230000037182 bone density Effects 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 7
- 239000003292 glue Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 4
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 3
- 239000001639 calcium acetate Substances 0.000 claims description 3
- 229960005147 calcium acetate Drugs 0.000 claims description 3
- 235000011092 calcium acetate Nutrition 0.000 claims description 3
- 229960003563 calcium carbonate Drugs 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 229960004256 calcium citrate Drugs 0.000 claims description 3
- 229940099148 glucosamine sulfate potassium chloride Drugs 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- 229940092124 calcium citrate malate Drugs 0.000 claims description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940060184 oil ingredients Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 10
- 238000005516 engineering process Methods 0.000 abstract description 5
- 235000013402 health food Nutrition 0.000 abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002285 corn oil Substances 0.000 abstract 1
- 235000005687 corn oil Nutrition 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 208000001132 Osteoporosis Diseases 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 3
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a krill oil softgel for protecting bone health as well as a preparation method and an application thereof, and belongs to the field of health food technology. Krill oil, glucosamine salt, a calcium source and corn oil are mixed with stirring, high pressure homogenization is carried out, pill pressing is carried out with a capsule body, moulding is carried out, pills are washed, drying is carried out, and the krill oil softgels are prepared. The krill oil, glucosamine, and the calcium agent are compounded, high pressure homogenization technology is used for preparing contents, and the obtained softgel product has good and substantial treatment effects for increasing bone mineral density without other side-effects.
Description
Technical field
The present invention relates to a kind of soft capsule, particularly relate to a kind of krill oil soft capsule protecting bone health and its preparation method and application, belong to technical field of health care food.
Background technology
Osteoporosis is a kind of systematicness osteopathia, and its pathology is that the fine structure that bone amount declines with bone destroys, and the fragility showing as bone increases, thus the danger of fracture is greatly improved, even being also susceptible to fracture in slight wound or atraumatic situation. Osteoporosis is a kind of multifactor caused chronic disease. Before fracture occurs, generally without Special Clinical Manifestation. This disease women is more common in male, is common in postmenopausal women and old people. It is reported, at present in more than 50 years old crowd of China, patients with primary osteoporosis reaches more than 8,000 ten thousand, just has 1-2 name to suffer from this sick in every 5 postmenopausal womens. Osteoporosis ranking in international epidemic, has risen to the 6th, is referred to as " soundless epidemic diseases ", and the incidence of fracture caused because of osteoporosis also dramatically increases. Osteoporotic fracture is dangerous is 39.7% in women, and male is 13.1%. Expecting the year two thousand twenty-the year two thousand fifty, the patients with osteoporosis of China is up to 2.87 hundred million. Current clinical medicine business, the drug main for the treatment of osteoporosis to have: anti-bone resorption medicine, promoting bone growing medicine and microorganism D class medicine. Although western medicine effect is good, but long-term taking can produce some side effect, and as have effect health food can auxiliary treatment osteoporosis, safety has no side effect, and has good preventive effect.
Krill oil: be derived from the South Pole, the mode that ultralow temperature extracts is utilized to extract, it is that the Nature is presented to the natural health food of the mankind, antarctic krill oil is rich in phospholipid, phosphatide type unsaturated fatty acid (EPA/DHA), phosphatide type astaxanthin (superpower polyphenoils), the plurality of active ingredients such as choline, various compositions are coordinated to promote, antarctic krill oil is made to possess as regulated blood fat, reduce cholesterol, improve hyperlipidemia, nourishing the brain and improving intelligence, active thinking, prevention senile dementia, free radical resisting, delaying aging, improve body cell nutrition, improve immunity, support the multiple special efficacies that human body is useful such as vision health.
The product of current antarctic krill oil is concentrated mainly on and regulates blood fat, improves in the research of cardiovascular and cerebrovascular vessel, but yet there are no relevant report and research in improving bone health, pre-preventing bone rarefaction product, in addition, antarctic krill oil distinctive composition phospholipid itself, its higher content and the affinity with human body cell film so that it has good bioavailability.
It addition, colloid mill technology conventional in present soft capsule, simply by physical actions such as grindings, soft capsule content itself is carried out order number reduction, reduce blocking, effectively do not improve the biological utilisation effect of product.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, it is provided that a kind of krill oil soft capsule protecting bone health and its preparation method and application.
The technical scheme is that a kind of krill oil soft capsule protecting bone health; its raw material is krill oil, glucosamine salt, calcium source and Semen Maydis oil, and krill oil, glucosamine salt, calcium source and Semen Maydis oil mass ratio are (8～15): (15～25): (20～31): (40～45).
The preparation method that second aspect present invention discloses aforementioned krill oil soft capsule, comprises the following steps:
(1) Feedstock treating: be (8～15) in mass ratio by krill oil, glucosamine salt, calcium source and Semen Maydis oil: (15～25): (20～31): (40～45) mix and blend;
(2) high pressure homogenize: use homogenizer by the batch mixing high-speed homogenization 15～25min of step (1), it is incubated 12～20min at 55～60 DEG C, obtained liquid transfers to high pressure homogenizer, high pressure homogenize 12～20min is carried out under 80～120MPa pressure, circular treatment, obtains homogenizing content;
(3) preparing capsule utricule: inject in glue pot by glycerol and pure water, heated and stirred, to 75 DEG C, adds edible Gelatinum oxhide, continues stirring 20～30min final vacuum deaeration, prepares capsule utricule; The mass ratio of described glycerol, pure water and edible Gelatinum oxhide is (0.2～1): (0.3～0.6): (0.4～1);
(4) by the capsule utricule of the homogenizing content of step (2) and step (3) through pelleting, molding, wash ball, dry, prepare krill oil soft capsule.
On the basis of technique scheme, the preparation method of the present invention can also do following improvement.
Further, described in step (1), the particle size range in glucosamine salt and calcium source is 80～400 orders.
Further, described glucosamine salt is one or both mixing of glucosamine hydrochloride or Glucosamine sulfate potassium chloride.
Further, described calcium source is one or more mixing of calcium acetate, calcium citrate, calcium carbonate or calcium citrate malate.
In the krill oil soft capsule content that the inventive method obtains, calcium content maintains 4～12wt%, and content of phospholipid maintains 3～6wt%, and glucosamine salt content maintains 14～25wt%.
The colloid mill technology that present soft capsule field is conventional, simply by physical actions such as grindings, carries out order number reduction to soft capsule content itself, the not effective biological utilisation effect improving product. And the present invention passes through high pressure homogenization technique; and coordinate the raw materials such as the phospholipid in natural krill oil, unsaturated fatty acid, astaxanthin; can be good at promoting other raw materials are carried out portion envelops; thus effective ingredient being protected, delivering and slow release; the forming portion cyto-architectural liposome of classification, improves the bioavailability of product.
Third aspect present invention discloses the application in protection bone health, increase bone density of the aforementioned krill oil soft capsule.
Further, the dosage of described krill oil soft capsule is 3～4g/ days.
The invention has the beneficial effects as follows: the present invention is undertaken composite by krill oil, D-glucosamine, calcium preparation, and carry out content liposomal preparation by high pressure homogenization technique, the soft gel products obtained has good therapeutical effect to increasing bone density, and effect is notable, without other side effect.
Detailed description of the invention
Below in conjunction with example, principles of the invention and feature being described, example is served only for explaining the present invention, is not intended to limit the scope of the present invention.
The preparation of embodiment 1 krill oil soft capsule
(1) Feedstock treating: be 8:25:22:45 mix and blend in mass ratio by krill oil, glucosamine hydrochloride, calcium acetate and Semen Maydis oil;
(2) high pressure homogenize: use homogenizer by the batch mixing high-speed homogenization 25min of step (1), being incubated 12min at 55 DEG C, obtained liquid transfers to high pressure homogenizer, carries out high pressure homogenize 12min under 80MPa pressure, circular treatment, obtains homogenizing content;
(3) preparing capsule utricule: inject in glue pot by glycerol and pure water, heated and stirred, to 75 DEG C, adds edible Gelatinum oxhide, continues stirring 20～30min final vacuum deaeration, prepares capsule utricule; The mass ratio of described glycerol, pure water and edible Gelatinum oxhide is 1:0.55:1;
(4) by the capsule utricule of the homogenizing content of step (2) and step (3) through pelleting, molding, wash ball, dry, prepare krill oil soft capsule.
After testing, in the krill oil soft capsule content that the present embodiment obtains, calcium content maintains 5.5wt%, and content of phospholipid maintains 3wt%, and glucosamine salt content maintains 24wt%.
The preparation of embodiment 2 krill oil soft capsule
(1) Feedstock treating: be 15:20:25:40 mix and blend in mass ratio by krill oil, glucosamine hydrochloride, calcium citrate and Semen Maydis oil;
(2) high pressure homogenize: use homogenizer by the batch mixing high-speed homogenization 20min of step (1), being incubated 16min at 55 DEG C, obtained liquid transfers to high pressure homogenizer, carries out high pressure homogenize 15min under 100MPa pressure, circular treatment, obtains homogenizing content;
(3) preparing capsule utricule: inject in glue pot by glycerol and pure water, heated and stirred, to 75 DEG C, adds edible Gelatinum oxhide, continues stirring 20～30min final vacuum deaeration, prepares capsule utricule; The mass ratio of described glycerol, pure water and edible Gelatinum oxhide is 0.2:0.3:0.4;
(4) by the capsule utricule of the homogenizing content of step (2) and step (3) through pelleting, molding, wash ball, dry, prepare krill oil soft capsule.
After testing, in the krill oil soft capsule content that the present embodiment obtains, calcium content maintains 4.5wt%, and content of phospholipid maintains 6wt%, and glucosamine salt content maintains 19wt%.
The preparation of embodiment 3 krill oil soft capsule
(1) Feedstock treating: be 12:15:31:42 mix and blend in mass ratio by krill oil, Glucosamine sulfate potassium chloride, calcium carbonate and Semen Maydis oil;
(2) high pressure homogenize: use homogenizer by the batch mixing high-speed homogenization 15min of step (1), being incubated 16min at 58 DEG C, obtained liquid transfers to high pressure homogenizer, carries out high pressure homogenize 20min under 120MPa pressure, circular treatment, obtains homogenizing content;
(3) preparing capsule utricule: inject in glue pot by glycerol and pure water, heated and stirred, to 75 DEG C, adds edible Gelatinum oxhide, continues stirring 20～30min final vacuum deaeration, prepares capsule utricule; The mass ratio of described glycerol, pure water and edible Gelatinum oxhide is 0.7:0.5:0.7;
(4) by the capsule utricule of the homogenizing content of step (2) and step (3) through pelleting, molding, wash ball, dry, prepare krill oil soft capsule.
After testing, in the krill oil soft capsule content that the present embodiment obtains, calcium content maintains 12wt%, and content of phospholipid maintains 4.8%, and glucosamine salt content maintains 14wt%.
Embodiment 4 zoopery
1. experimental technique
1.1 experimental raw
The krill oil soft capsule that embodiment 3 obtains
1.2 animal packet and dose design
50 cleaning grade SD kind rats are randomly divided into 5 groups, namely low calcium matched group, high dose calcium carbonate group, 3 dosage groups of krill oil soft capsule, every treated animal 10.Krill oil soft capsule human intaking amount is 60mg/kg.bw, sets basic, normal, high 3 dosage groups, i.e. 300mg/kg.bw, 600mg/kg.bw, 1800mg/kg.bw groups respectively with the 5 of this dosage, 10,30 times. The calcium carbonate of high dose calcium carbonate control group and 540mg/kg.bw, this dosage is equivalent to krill oil soft capsule high dose group calcium level. Low calcium synthetic diet, by " health food inspection and assessment technique specification " formula, controls calcium content less than 1500mg/kg.
1.3 medications
Tested material is mixed in low calcium feedstuff and give animal. Take in the rule of 10g feedstuff according to every 100g body weight rat every day, during the preparation of basic, normal, high dose of test thing, take tested material 3g respectively, 6g, 18g add low calcium feedstuff to 1000g, mixing. Low calcium matched group gives low calcium feedstuff. Calcium carbonate control group: take calcium carbonate 5.4g (calcium content is 40%) and add low calcium feedstuff to 1000g, mixing, be equivalent to tested material high dose. From on-test, each treated animal, all single cage is raised, and feed each organizes feedstuff, drinks deionized water, records food-intake. Mix the ratio of low calcium feedstuff when experiment terminates according to the total food-intake of rat and tested material, calculate often group rat experiment respectively and take in the amount of tested material, totally 12 weeks.
1.4 process and observation index
Femoral bmd measures: when experiment terminates, sacrificed by decapitation rat, peels off right femur, toasts 8h through 108 DEG C, after being cooled to room temperature, measure femur midpoint and the bone width (BW) of distal end, bone mineral content (BMC) and bone density (BMD).
The mensuration of calcium content of bone: after weighing the gross weight of femur, put in the triangular flask of HCl treatment dry cleansing, add nitric acid+perchloric acid (4:1) mixed acid 8ml, after digestion, it is settled to 10ml with deionized water, measures with atomic absorption spectrophotometer.
1.5 experimental data statistics
Adopting SPSS software to carry out variance analysis, result system represents with mean+SD.
2. experimental result
The impact (x ± s) on rat femur center and the Bone mineral content and bone density of femur distal end of table 1 tested material
The impact (x ± s) on rat femur weight, calcium content of bone and TC of table 2 tested material
Note: * P < 0.05 compares with low calcium matched group, * * P < 0.01 compares with low calcium matched group.
Experimental result shows:
The high dose experimental group rat femur center of krill oil soft capsule and femur distal end content of mineral substances are noticeably greater than low calcium matched group (P < 0.01), middle and high dosage experiments group rat femur center bone density and high dose experimental group rat femur distal end bone density and are noticeably greater than calcium matched group (P < 0.05 or P < 0.01);
The femur weight of the high dose group rat of krill oil soft capsule is noticeably greater than low calcium matched group (P < 0.01), and the femur calcium content of middle and high dosage group rat and TC are noticeably greater than low calcium matched group (P < 0.05 or P < 0.01).
3. result conclusion
The krill oil soft capsule of the present invention can dramatically increase osteoporosis model rat femur bone density and calcium content of bone, has and well improves osteoporosis and increase effect of bone density.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all within the spirit and principles in the present invention, any amendment of making, equivalent replacement, improvement etc., should be included within protection scope of the present invention.
Claims (6)
1. the krill oil soft capsule protecting bone health; it is characterized in that; its raw material is krill oil, glucosamine salt, calcium source and Semen Maydis oil, and krill oil, glucosamine salt, calcium source and Semen Maydis oil mass ratio are (8～15): (15～25): (20～31): (40～45).
2. the preparation method protecting the krill oil soft capsule of bone health described in claim 1, it is characterised in that comprise the following steps:
(1) Feedstock treating: be (8～15) in mass ratio by krill oil, glucosamine salt, calcium source and Semen Maydis oil: (15～25): (20～31): (40～45) mix and blend;
(2) high pressure homogenize: use homogenizer by the batch mixing high-speed homogenization 15～25min of step (1), it is incubated 12～20min at 55～60 DEG C, obtained liquid transfers to high pressure homogenizer, high pressure homogenize 12～20min is carried out under 80～120MPa pressure, circular treatment, obtains homogenizing content;
(3) preparing capsule utricule: inject in glue pot by glycerol and pure water, heated and stirred, to 75 DEG C, adds edible Gelatinum oxhide, continues stirring 20～30min final vacuum deaeration, prepares capsule utricule; The mass ratio of described glycerol, pure water and edible Gelatinum oxhide is (0.2～1): (0.3～0.6): (0.4～1);
(4) by the capsule utricule of the homogenizing content of step (2) and step (3) through pelleting, molding, wash ball, dry, prepare krill oil soft capsule.
3. preparation method according to claim 2, it is characterised in that described in step (1), the particle size range in glucosamine salt and calcium source is 80～400 orders.
4. preparation method according to claim 2, it is characterised in that described glucosamine salt is one or both mixing of glucosamine hydrochloride or Glucosamine sulfate potassium chloride.
5. preparation method according to claim 2, it is characterised in that described calcium source is one or more mixing of calcium acetate, calcium citrate, calcium citrate malate or calcium carbonate.
6. protect the krill oil soft capsule of bone health at protection bone health described in claim 1, increase the application in bone density.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028631.3A CN105661509A (en) | 2016-01-18 | 2016-01-18 | Krill oil softgel for protecting bone health as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610028631.3A CN105661509A (en) | 2016-01-18 | 2016-01-18 | Krill oil softgel for protecting bone health as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105661509A true CN105661509A (en) | 2016-06-15 |
Family
ID=56301044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610028631.3A Pending CN105661509A (en) | 2016-01-18 | 2016-01-18 | Krill oil softgel for protecting bone health as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105661509A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106509890A (en) * | 2016-10-31 | 2017-03-22 | 烟台新时代健康产业有限公司 | Composition for relieving female climacteric syndrome and preparation method thereof |
| CN109106729A (en) * | 2018-07-26 | 2019-01-01 | 深圳先进技术研究院 | Antarctic krill oil-oyster calcium powder capsule |
| CN109170916A (en) * | 2018-11-02 | 2019-01-11 | 丽睿客信息科技（北京）有限公司 | One kind keeps fit and healthy food compositions and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102150836A (en) * | 2010-12-23 | 2011-08-17 | 烟台理博天然药物开发有限公司 | Ammonia sugar peptide soft capsule |
| CN104068306A (en) * | 2014-06-18 | 2014-10-01 | 广州市赛健生物科技有限公司 | Health food for improving bone density and preparation method of health food |
| US20140335226A1 (en) * | 2013-05-08 | 2014-11-13 | Lawrence I. Bell | Nutritious beverage formed from fluid acid whey and a method of forming a nutritious beverage by combining fluid acid whey and a juice |
| CN104873950A (en) * | 2015-06-14 | 2015-09-02 | 威海紫光金奥力生物技术有限公司 | Fishbone glucosamine preparation for increasing bone mineral density and production method thereof |
| CN104886553A (en) * | 2015-04-30 | 2015-09-09 | 威海特伦斯生物工程有限公司 | A production method of a preparation for alleviating osteoporosis and increasing bone mineral density |
| CN105147734A (en) * | 2015-09-21 | 2015-12-16 | 浙江大学 | Euphausia superba oil nanostructure lipid carrier and preparing method thereof |
-
2016
- 2016-01-18 CN CN201610028631.3A patent/CN105661509A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102150836A (en) * | 2010-12-23 | 2011-08-17 | 烟台理博天然药物开发有限公司 | Ammonia sugar peptide soft capsule |
| US20140335226A1 (en) * | 2013-05-08 | 2014-11-13 | Lawrence I. Bell | Nutritious beverage formed from fluid acid whey and a method of forming a nutritious beverage by combining fluid acid whey and a juice |
| CN104068306A (en) * | 2014-06-18 | 2014-10-01 | 广州市赛健生物科技有限公司 | Health food for improving bone density and preparation method of health food |
| CN104886553A (en) * | 2015-04-30 | 2015-09-09 | 威海特伦斯生物工程有限公司 | A production method of a preparation for alleviating osteoporosis and increasing bone mineral density |
| CN104873950A (en) * | 2015-06-14 | 2015-09-02 | 威海紫光金奥力生物技术有限公司 | Fishbone glucosamine preparation for increasing bone mineral density and production method thereof |
| CN105147734A (en) * | 2015-09-21 | 2015-12-16 | 浙江大学 | Euphausia superba oil nanostructure lipid carrier and preparing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 蔡维望等: "南极磷虾对大鼠骨质疏松模型的影响", 《中国生物学制品学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106509890A (en) * | 2016-10-31 | 2017-03-22 | 烟台新时代健康产业有限公司 | Composition for relieving female climacteric syndrome and preparation method thereof |
| CN109106729A (en) * | 2018-07-26 | 2019-01-01 | 深圳先进技术研究院 | Antarctic krill oil-oyster calcium powder capsule |
| CN109170916A (en) * | 2018-11-02 | 2019-01-11 | 丽睿客信息科技（北京）有限公司 | One kind keeps fit and healthy food compositions and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260028B1 (en) | Skin care preparations for babies | |
| CN101361970B (en) | Composition with beauty effect and health care efficacy and use thereof | |
| AU2393701A (en) | Pharmaceutical and cosmetic carrier or composition for topical application | |
| CN105053256A (en) | Flavored nutrition balanced blend oil | |
| US20210177912A1 (en) | Non-winterized, standardized marine source oil products and methods of making thereof | |
| CN105661509A (en) | Krill oil softgel for protecting bone health as well as preparation method and application thereof | |
| CN107691838A (en) | Pet sterilization sustained release cream and preparation method thereof | |
| CN104957603B (en) | Improving memory type nutritious supplementary and its preparation method | |
| CN106035938A (en) | Lutein ester tableting candy and preparation method thereof | |
| CN105640828B (en) | Application of the durian shell extract in oral care product | |
| CN110150664A (en) | A kind of rose functional food improving acne | |
| WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| WO2014134834A1 (en) | Composition and food comprising same and preparation method of food | |
| JPH09238615A (en) | Health nutritive food | |
| CN102772351B (en) | Pearl E cream | |
| TWI624477B (en) | Peptide composition and use thereof | |
| CN102106930B (en) | Mixture with antioxidant and liver-protecting functions and manufacturing method thereof | |
| KR101645535B1 (en) | Composition containing glucosamine with anti-immflammatory and pain repression effect | |
| CN102948663A (en) | Rana japonica oil granules and preparation method thereof | |
| CN112514996B (en) | Combination or composition, dairy product and use | |
| CN102178791B (en) | Toxin expelling and acne removing agent and preparation method and use method thereof | |
| CN106668611B (en) | Traditional Chinese medicine composition for promoting generation of brown adipose tissues and preparation method thereof | |
| CN106902273A (en) | Prevent and treat pharmaceutical composition, eczema ointment of infant eczema and preparation method thereof | |
| CA2745579A1 (en) | Thick pine needle extract composition for capsulation | |
| CN105707864A (en) | Formula of anti-senility medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |